1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012
2. Opdivo (Nivolumab) [package insert]. Princeton, NJ; Bristol-Myers Squibb; Revised 04/2018. 06/15/2018]; Available from: http://packageinserts.bms.com/pi/pi_opdivo.pdf.
3. KEYTRUDA (pembrolizumab) [package insert]. Whitehouse Station, NJ; Merck & Co., Inc; Revised 06/2018. 06/15/2018]; Available from: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
4. TECENTRIQ (atezolizumab) [package insert]. Genentech, Inc. South San Francisco, CA. Revised 04/2018. 6/15/2018]; Available from: http://www.gene.com/download/pdf/tecentriq_prescribing.pdf.
5. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials;El Osta;Crit Rev Oncol Hematol,2017